Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial
来那度胺、地塞米松和阿仑单抗或奥法木单抗治疗高危慢性淋巴细胞白血病:NCRI CLL210 试验的最终结果
期刊:Haematologica
影响因子:8.2
doi:10.3324/haematol.2019.230805
Andrew R Pettitt, Richard Jackson, Silvia Cicconi, Fotis Polydoros, Christina Yap, James Dodd, Matthew Bickerstaff, Michael Stackpoole, Umair T Khan, Stacey Carruthers, Melanie Oates, Ke Lin, Sarah E Coupland, Geetha Menon, Nagesh Kalakonda, Helen McCarthy, Adrian Bloor, Anna Schuh, Andrew Duncombe,